Semaglutide in oral form: what the evidence actually shows

What the OASIS 4 trial found — and how to read those numbers honestly

The phase 3 evidence behind the MHRA's approval comes from OASIS 4: a 64-week, placebo-controlled trial of 307 adults living with obesity or overweight alongside at least one weight-related condition, none of whom had type 2 diabetes. All participants followed a reduced-calorie diet and increased their activity levels alongside treatment. On that combined programme, those receiving oral semaglutide lost an average of around 13.6% of their body weight, compared with approximately 2.4% in the placebo group. Among participants who stayed fully adherent to every dose throughout the trial, the figure reached roughly 17%.

Two things are worth holding in mind when you see these numbers quoted elsewhere. First, the 17% figure applies specifically to full adherers, it is not the overall trial average, and framing it as such would misrepresent the data. Second, both the 13.6% and the 17% figures reflect semaglutide used alongside genuine lifestyle changes, not in place of them. That context matters clinically. The most common side effects in the trial were gastrointestinal (reported by around 74% of those on oral semaglutide compared with 42% of those on placebo) and were generally mild to moderate, tending to ease as the body adjusted to treatment. You can read the MHRA's published communications on semaglutide approvals for the regulatory context behind this programme.

A question our prescribers hear most weeks is whether these results are comparable to the injection. Broadly, the injection's STEP 1 trial (conducted over 68 weeks at the 2.4mg weekly maintenance dose) showed around 15% average weight loss. The oral tablet produces somewhat lower average results, though the gap narrows considerably among consistent users. For the evidence behind the injectable version, our Wegovy tablets overview sets out both options alongside each other.

How oral semaglutide is taken, and why the dosing window matters

The escalation schedule for Wegovy tablets runs from 1.5mg once daily, through 4mg and 9mg, up to a 25mg maintenance dose, with a minimum of one month at each level before the prescriber considers moving upward. People who are already established on the 2.4mg weekly injection may be able to transition directly to the 25mg tablet, but that decision sits with the prescriber, not the patient.

The administration requirement is specific and worth understanding before starting. The tablet must be taken first thing in the morning on an empty stomach, with no more than a small amount of plain water, up to around 120ml. After swallowing, you wait at least 30 minutes before eating, drinking anything else (including coffee or tea), or taking other oral medicines. This is not arbitrary: the absorption mechanism depends on an empty stomach and the correct volume of water. Missing this window consistently can reduce how much semaglutide actually reaches the bloodstream. For the precise instructions, the patient information leaflet that comes with your prescription is the definitive reference, and your prescriber will go through this with you.

Storage is notably simpler than with the injection: no refrigeration, no cold chain to maintain while travelling. The tablets can be kept at room temperature, which some people find makes a real practical difference to daily life. For a detailed look at how the tablet compares with other oral options, this page on the pill form of semaglutide goes further.

Who the oral form is licensed for, and the Rybelsus distinction

The MHRA licensed Wegovy tablets for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition, for example, high blood pressure, dyslipidaemia, type 2 diabetes or obstructive sleep apnoea. These thresholds reflect the licensed indication; a prescriber assesses the full picture before recommending any treatment, and BMI alone does not determine suitability.

One confusion that comes up regularly: Rybelsus is also oral semaglutide, but it is licensed for type 2 diabetes management at doses of 3mg, 7mg and 14mg, not for weight loss. Those are different strengths, a different licensed indication, and a different product. The weight-management tablet schedule (1.5mg, 4mg, 9mg, 25mg) is specific to Wegovy tablets, and the two products should never be treated as interchangeable. If you've seen Rybelsus mentioned in a weight-loss context, it was being used outside its licence. The NHS medicines page for semaglutide explains the licensed indications clearly.

Wegovy tablets are not currently available on the NHS, a NICE appraisal would need to precede any NHS commissioning decision. That means the route to them, for now, is a private prescription following a clinical assessment. If you want to explore what that involves, more detail on semaglutide oral tablets covers the practical steps. Questions about cost context are addressed separately on where to buy semaglutide tablets in the UK, and our page on semaglutide tablet effectiveness examines the evidence in more depth.

Safety, side effects, and the practicalities of starting

The gastrointestinal side effects seen in OASIS 4 (nausea, vomiting, diarrhoea, constipation, reflux) are consistent with what the semaglutide injection produces, and with the GLP-1 class generally. They tend to be most noticeable in the first few weeks of a new dose and typically settle as the body adjusts. Starting at the lowest dose and titrating slowly is the approach used in the trial and reflected in the licensed schedule, it exists precisely to give your system time to adapt.

There are situations where these medicines require particular caution or are not appropriate. They are not recommended during pregnancy, while breastfeeding, or when trying to conceive. They are not licensed for people under 18. A personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, or certain gastrointestinal conditions would all need prescriber discussion before starting. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but potentially serious risk across the GLP-1 class: severe, persistent abdominal pain that radiates to the back warrants prompt medical attention. Any suspected side effect can be reported through the MHRA's Yellow Card scheme.

If you'd like to talk through whether the oral form might be appropriate for your situation, starting a free consultation connects you with a GPhC-registered prescriber who will review your case the same day. There's no obligation, and the consultation itself costs nothing.